CEimpact Podcast

One of the oldest medications in our pharmacopeia is digoxin. It may be used for atrial fibrillation and heart failure, although not as a first-line agent. Despite this, digoxin use is on the rise. Join host, Geoff Wall, as he evaluates why more prescribers are using digoxin.

The GameChanger
No new randomized controlled trials have been published to justify the increased use of digoxin. However, when used, providers should routinely monitor digoxin levels.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Gazzaniga G, Menichelli D, Scaglione F, et al. Effect of digoxin on all-cause and cardiovascular mortality in patients with atrial fibrillation with and without heart failure: an umbrella review of systematic reviews and 12 meta-analyses. Eur J Clin Pharmacol. 2023 Apr;79(4):473-483. doi: 10.1007/s00228-023-03470-y. Epub 2023 Mar 6. PMID: 36872367; PMCID: PMC10039090.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039090/

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Apply information on the potential uses and harms of digoxin
2. Apply a strategy for monitoring digoxin in heart failure patients

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-400-H01-P
Initial release date: 12/18/2023
Expiration date: 12/18/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Join Ashlee as she talks with Jen Moulton, the president of CEimpact, about her top five takeaways from a transformative year in pharmacy education and patient care. 

Listen to this episode to reflect on, learn, and apply the biggest lessons 2023 taught us, from the every-day practices that define us to the big picture within pharmacy education that leads us. 

In this episode, the two discuss:
- The power of focus, prioritization, and efficient processes within CEimpact.
- Technology's ever-growing influence on pharmacy education.
- How building connections with clients, team members, and customers can prevent burnout and foster positivity.
- CEimpact's efforts to address pharmacy burnout.

To learn more about CEimpact's By Design memberships, click here. 

Follow CEimpact on Social Media:
LinkedIn
Instagram

Alzheimer's Disease is a progressive terminal disease. Many treatments are focused on lifestyle modification to delay diagnosis and onset. Join host, Geoff Wall, with guest Jake Galdo, as they look at a new study evaluating the association between vaccines and the development of Alzheimer's Disease.
 
The GameChanger
Postviral inflammation may play a role in the development of Alzheimer's Disease. A recent claims-based study found an association between immunization status and the development of Alzheimer's Disease.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Jake Galdo, PharmD, MBA, BCPS, BCGP
Course Content and Developer, CEimpact
Managing Network Facilitator, CPESN Health Equity
CEO, Seguridad
 
Reference
Harris K, Ling Y, Bukhbinder AS, et al. The Impact of Routine Vaccinations on Alzheimer's Disease Risk in Persons 65 Years and Older: A Claims-Based Cohort Study using Propensity Score Matching. J Alzheimers Dis. 2023;95(2):703-718. doi: 10.3233/JAD-221231. PMID: 37574727; PMCID: PMC10578243.
 
Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the potential mechanisms of inflammation and viral infections with the development of Alzheimer's Disease.
2. Describe the study discussed and its application in guiding patients to receive vaccines.

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-367-H01-P
Initial release date: 12/11/2023
Expiration date: 12/11/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Exocrine enzyme dysfunction is far more common than many primary care practitioners realize. Using pancreatic enzymes can help with symptoms and vitamin absorption. Join host, Geoff Wall, as he reviews new guidelines on the appropriate use of pancreatic enzymes.
 
The GameChanger
Chronic pancreatitis is the most common cause of exocrine dysfunction in adults. All pancreatic enzymes are equally effective; however, the use of pancreatic enzymes to treat chronic pain is controversial.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Whitcomb DC, Buchner AM, Forsmark CE. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review. Gastroenterology. 2023 Nov;165(5):1292-1301. doi: 10.1053/j.gastro.2023.07.007. Epub 2023 Sep 20. PMID: 37737818.

https://www.gastrojournal.org/article/S0016-5085(23)04780-7/fulltext
 
Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss common symptoms and diagnoses associated with exocrine dysfunction.
2. Describe challenges associated with the use of pancreatic enzymes.

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-366-H01-P
Initial release date: 12/4/2023
Expiration date: 12/4/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The world of healthcare is changing and so are our students and residents. If you are in a precepting role, you are experiencing some challenges in navigating these new waters.

In this episode, Logan Murry, CPD champion, makes professional development practical, effective, and intentional. Listen in to learn how taking time to practice intentional CPD can make you a more effective, and more fulfilled preceptor.

Host
Kathy Schott, PhD
Vice President, Education & Operations
CEimpact

Guest
Logan T. Murry, PharmD, PhD
Assistant Director of the Continuing Pharmacy Education Accreditation Program
Accreditation Council for Pharmacy Education (ACPE)

Get CE: CLICK HERE TO CPE CREDIT FOR THE COURSE!

CPE Information
 
Learning Objectives
At the end of this course, preceptors will be able to:
1. Describe the Continuing Professional Development (CPD) cycle and its key components.
2. Articulate the value of practicing intentional CPD as a preceptor.

0.05 CEU/0.5 Hr
UAN: 0107-0000-26-368-H99-P 
Initial release date: 11/29/2026
Expiration date: 11/29/2029
Additional CPE details can be found here.

The speakers have no relevant financial relationships with ineligible companies to disclose.

This program has been:
Approved by the Minnesota Board of Pharmacy as education for Minnesota pharmacy preceptors.

Reviewed by the Texas Consortium on Experiential Programs and has been designated as preceptor education and training for Texas preceptors.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Menopausal vasomotor symptoms occur in about 80% of women and have a significant impact on quality of life. Hormone replacement therapy works well; however, it is often underused. Join host, Geoff Wall, as he evaluates Fezolinetant, a new medication to treat 'hot flashes.'

The GameChanger
HRT is vastly underused in menopausal women. Gabapentin and SNRIs may help with some vasomotor symptoms. Fezolinetant is effective for hot flashes and seems to be well tolerated.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023 Apr 1;401(10382):1091-1102. doi: 10.1016/S0140-6736(23)00085-5. Epub 2023 Mar 13. PMID: 36924778.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00085-5/fulltext

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the pros and cons of hormone replacement therapy in women with vasomotor symptoms.
2. Discuss the role of fezolinetant for treatment of vasomotor symptoms. 

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-365-H01-P
Initial release date: 11/27/2023
Expiration date: 11/27/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Respiratory failure from COVID-19 should be treated as soon as possible. Join host, Geoff Wall, as he evaluates the the role of convalescent plasma in treating patients with COVID-19 and on mechanical ventilation.
 
The GameChanger
COVID-19 is still a significant concern acutely and for long-term complications. Convalescent plasma may benefit severely ill COVID-19 patients on mechanical ventilation and with acute respiratory distress syndrome (ARDS).
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Misset B, Piagnerelli M, Hoste E, Dardenne N, Grimaldi D, Michaux I, De Waele E, Dumoulin A, Jorens PG, van der Hauwaert E, Vallot F, Lamote S, Swinnen W, De Schryver N, Fraipont V, de Mey N, Dauby N, Layios N, Mesland JB, Meyfroidt G, Moutschen M, Compernolle V, Gothot A, Desmecht D, Taveira da Silva Pereira MI, Garigliany M, Najdovski T, Bertrand A, Donneau AF, Laterre PF. Convalescent Plasma for Covid-19-Induced ARDS in Mechanically Ventilated Patients. N Engl J Med. 2023 Oct 26;389(17):1590-1600. doi: 10.1056/NEJMoa2209502. Epub 2023 Oct 25. PMID: 37889107.

https://www.nejm.org/doi/full/10.1056/NEJMoa2209502?query=featured_home

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the latest NIH treatment guidelines for COVID-19 patients who are hospitalized
2. Describe the use of convalescent plasma in the context of a COVID-19 treatment algorithm

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-354-H01-P
Initial release date: 11/20/2023
Expiration date: 11/20/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Join Ashlee as she talks with Derek Borkowski, CEO and founder of Pyrls about the journey that led to the creation of Pyrls. Alongside this, Derek discusses Pyrls' partnership with CEimpact and the future of Pyrls  as a company.

Pyrls is an online drug information provider that focuses on design and simplicity in their delivery of that information. Through an deeper dive into Pyrls, this episode offers up an exclusive behind-the-scenes glimpse into the future of digital health and the role of technology in the medical field. 

In this episode, the two discuss:
- The creation of Pyrls
- Pyrls' impact on the healthcare world
- Pyrls' partnership with CEimpact
- The future of Pyrls

To learn more about CEimpact's By Design memberships, click here. 

Follow CEimpact on Social Media:
LinkedIn
Instagram

description
 
Host
Kathy Schott, PhD
Vice President, Education & Operations
CEimpact

Guest
name

About
text

Get CE: CLICK HERE TO CPE CREDIT FOR THE COURSE!

CPE Information
 
Learning Objectives
At the end of this course, preceptors will be able to:
1. a

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-X-H99-P
Initial release date: X/X/2023
Expiration date: X/X/2024
Additional CPE details can be found here.

The speakers have no relevant financial relationships with ineligible companies to disclose.

This program has been:
Approved by the Minnesota Board of Pharmacy as education for Minnesota pharmacy preceptors.

Reviewed by the Texas Consortium on Experiential Programs and has been designated as preceptor education and training for Texas preceptors.

Want more information on this and related topics?

Title
description

Follow CEimpact on Social Media:
LinkedIn
Instagram

Download the CEimpact App for Free Continuing Education + so much more!

Piperacillin/tazobactam and vancomycin have been reported in numerous clinical trials to be associated with acute kidney injury. Comparatively, cefepime with vancomycin may increase neurotoxic effects. Join host, Geoff Wall, as he evaluates a new randomized controlled trial evaluating the safety of these medications.
 
The GameChanger
Vancomycin, even at appropriate doses, can cause nephrotoxicity. Piperacillin/tazobactam does not seem to increase the risk of adverse kidney outcomes. However, cefepime is associated with an increased risk of neurologic toxicity.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Tong SYC, Venkatesh B, McCreary EK. Acute Kidney Injury With Empirical Antibiotics for Sepsis. JAMA. 2023;330(16):1531–1533. doi:10.1001/jama.2023.18591

https://jamanetwork.com/journals/jama/fullarticle/2810593

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the risk of nephrotoxicity with piperacillin/tazobactam
2. Discuss the factors that exacerbate neurologic adverse effects with cefepime

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-353-H01-P
Initial release date: 11/13/2023
Expiration date: 11/13/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram